PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 02/28/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends PHXM vs. ATRA, ELYM, DTIL, NRXP, OVID, RAPT, KALA, GBIO, XLO, and VYNEShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Atara Biotherapeutics (ATRA), Eliem Therapeutics (ELYM), Precision BioSciences (DTIL), NRx Pharmaceuticals (NRXP), Ovid Therapeutics (OVID), RAPT Therapeutics (RAPT), KALA BIO (KALA), Generation Bio (GBIO), Xilio Therapeutics (XLO), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Atara Biotherapeutics Eliem Therapeutics Precision BioSciences NRx Pharmaceuticals Ovid Therapeutics RAPT Therapeutics KALA BIO Generation Bio Xilio Therapeutics VYNE Therapeutics PHAXIAM Therapeutics (NASDAQ:PHXM) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation. Which has stronger earnings & valuation, PHXM or ATRA? PHAXIAM Therapeutics has higher earnings, but lower revenue than Atara Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPHAXIAM Therapeutics$32.66M0.32-$240KN/AN/AAtara Biotherapeutics$100.44M0.42-$276.13M-$25.78-0.28 Does the media prefer PHXM or ATRA? In the previous week, Atara Biotherapeutics had 3 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 beat Atara Biotherapeutics' score of -0.09 indicating that PHAXIAM Therapeutics is being referred to more favorably in the media. Company Overall Sentiment PHAXIAM Therapeutics Neutral Atara Biotherapeutics Neutral Do institutionals and insiders hold more shares of PHXM or ATRA? 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer PHXM or ATRA? Atara Biotherapeutics has a consensus price target of $17.75, indicating a potential upside of 142.82%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Atara Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57 Does the MarketBeat Community favor PHXM or ATRA? Atara Biotherapeutics received 436 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformPHAXIAM TherapeuticsN/AN/AAtara BiotherapeuticsOutperform Votes43667.28% Underperform Votes21232.72% Which has more volatility and risk, PHXM or ATRA? PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Is PHXM or ATRA more profitable? PHAXIAM Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -132.58%. Company Net Margins Return on Equity Return on Assets PHAXIAM TherapeuticsN/A N/A N/A Atara Biotherapeutics -132.58%N/A -90.16% SummaryAtara Biotherapeutics beats PHAXIAM Therapeutics on 10 of the 15 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$116.55M$5.85B$8.44BDividend YieldN/A3.69%4.89%4.00%P/E RatioN/A3.1925.1819.39Price / Sales0.324,300.64389.45117.49Price / CashN/A13.0138.0534.62Price / Book0.3945.177.394.33Net Income-$240,000.00-$87.82M$3.18B$246.62M7 Day PerformanceN/A-1.47%-1.23%-1.45%1 Month PerformanceN/A-1.93%-6.36%-6.46%1 Year Performance2.99%149.82%14.76%5.20% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049ATRAAtara Biotherapeutics4.1132 of 5 stars$7.34+1.2%$17.75+141.8%-57.7%$42.28M$8.57M-0.28330ELYMEliem TherapeuticsN/A$1.42-3.4%N/A-48.6%$42.25MN/A-2.689Gap DownDTILPrecision BioSciences4.1558 of 5 stars$5.47-2.8%$37.67+588.6%-57.1%$41.96M$75.10M91.18200Positive NewsNRXPNRx Pharmaceuticals2.6681 of 5 stars$2.33-2.1%$31.67+1,259.1%-96.8%$40.26MN/A-1.092OVIDOvid Therapeutics4.58 of 5 stars$0.57-0.6%$4.03+611.7%-84.6%$40.24M$631,695.00-1.2160Gap UpRAPTRAPT Therapeutics4.102 of 5 stars$1.15-2.5%$5.29+359.6%-87.0%$40.20M$1.53M-0.4280KALAKALA BIO3.8609 of 5 stars$6.57-1.1%$15.00+128.3%+2.0%$40.02M$3.89M-0.5330GBIOGeneration Bio3.1717 of 5 stars$0.59-2.6%$6.50+1,005.4%-81.8%$39.27M$18.58M-0.27150XLOXilio Therapeutics2.9691 of 5 stars$0.89-5.1%$4.00+348.9%+14.5%$39.17MN/A-0.5270VYNEVYNE Therapeutics3.1237 of 5 stars$2.65-5.4%$6.88+159.4%+6.2%$39.09M$493,000.00-3.0830Positive News Related Companies and Tools Related Companies Atara Biotherapeutics Competitors Eliem Therapeutics Competitors Precision BioSciences Competitors NRx Pharmaceuticals Competitors Ovid Therapeutics Competitors RAPT Therapeutics Competitors KALA BIO Competitors Generation Bio Competitors Xilio Therapeutics Competitors VYNE Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHXM) was last updated on 3/6/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrillion-Dollar Crypto PlayAI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a br...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHXM Stock Alerts